RNXT today
$1.16-$0.06 (-4.92%)close Nov 12, 2026Trend
DailyUptrend (confirmed)
4 hourDescending Triangle
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns down below $0.70
Key levels
Resistance$1.52
Resistance$1.37
Support$1.09
Support$0.83
Latest news & SEC filings
AnalystAscendiant Capital lifts its valuation view on RenovoRx shares to $15.00
EarningsRenovoRx Posts Q3 2026 Earnings
EarningsRenovoRx posts Q3 adjusted loss of $0.07 per share, revenue $1.066M
EarningsRenovoRx holds Q3 2026 earnings call
All RNXT news →About RenovoRx
RenovoRx develops treatments that deliver cancer drugs directly to tumors and sells RenovoCath, a catheter cleared by the FDA for localized delivery of therapeutic agents. Its platform uses the device to force chemotherapy through blood vessel walls close to a tumor. The company is testing an intra-arterial gemcitabine combination in a late-stage trial for pancreatic tumors that cannot be surgically removed. RenovoCath is sold to cancer treatment centers across the United States.
Based on the company's 10-K filed Mar 30, 2026.
Nasdaq · Healthcare
RenovoRx, Inc. (RNXT)
What Is the Price Target for RNXT?
SEPT Low Target
$3.00
SEPT Mid Target
$3.00
SEPT High Target
$3.00
Analyst Consensus
$3.00
Is RNXT a Buy or Sell Right Now?
Thesis
- •Revenue growing 2511.6% YoY with UNKNOWN trend — consistent growth.
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for RNXT.
Start Free Trial →Is RNXT Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$2.38
28
Moat Score
NONE
3/9
Piotroski Score
-4.3
Altman Z-Score
What Is Smart Money Doing with RNXT?
Insider Signal
BUYING
5 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| VOLL MARK | officer | Buy | 80,000 | - | Sep 10, 2026 |
| VOLL MARK | officer | Buy | 25,000 | $20K | May 19, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →RNXT Growth Story
Revenue YoY
2511.6%
3yr Revenue CAGR
N/A%
EPS Growth YoY
20%
FCF Growth YoY
-20.1%
Revenue Trend
UNKNOWN
Dark Pool Trades for RNXT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for RNXT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:53:52 | $1.18 | 4,200 | $$5K | BUY |
| 20:38:21 | $1.17 | 4,760 | $$6K | SELL |
| 20:10:34 | $1.17 | 1,001 | $$1K | MIDPOINT |
| 19:30:57 | $1.17 | 8,500 | $$10K | BUY |
| 19:30:45 | $1.18 | 2,700 | $$3K | BUY |
5 dark pool trades shown · $$25K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for RenovoRx, Inc. (RNXT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →RNXT — frequently asked questions
What is RNXT stock price today?
RenovoRx, Inc. (RNXT) is at $1.16, down 4.92% (-$0.06) at the Nov 12, 2026 close.
Why is RNXT stock moving today?
Latest RNXT news — Nov 9, 2026: Ascendiant Capital lifts its valuation view on RenovoRx shares to $15.00 · Nov 6, 2026: RenovoRx Posts Q3 2026 Earnings
What is the RNXT price target?
The average analyst price target for RNXT is $3.00, ranging from $3 to $3, based on 1 analysts.
What do analysts rate RNXT?
Analyst ratings for RNXT: 0 Buy, 4 Hold, 0 Sell — consensus Hold.
Did RNXT beat earnings?
RNXT last reported on Aug 12, 2026: EPS -$0.05 vs -$0.07 expected — a beat of 31.0%.
Does RNXT pay a dividend?
RNXT does not currently pay a dividend.
What are RNXT support and resistance levels?
Support: $1.09, $0.83. Resistance: $1.37, $1.52, $1.73.
What are insiders doing with RNXT?
Insider activity: BUYING, 5 buys and 0 sells in the last 90 days.
What is the latest news on RNXT?
Nov 9, 2026: Ascendiant Capital lifts its valuation view on RenovoRx shares to $15.00 · Nov 6, 2026: RenovoRx Posts Q3 2026 Earnings · Nov 5, 2026: RenovoRx posts Q3 adjusted loss of $0.07 per share, revenue $1.066M